

Supplementary Material

Attributes, risk factors and outcomes of 15-month post-COVID syndrome in outpatients with and without SARS-CoV-2 vaccination: Results from a longitudinal, observational cohort study with case-control design

Max Augustin ^{1,2,3,†} and **Melanie Stecher** ^{1,3†}, Hauke Wüstenberg ¹, Veronica di Cristanziano ⁴, Ute Sandaradura de Silva ^{1,2,3}, Elisabeth Pracht ¹, Dominic Rauschning ¹, Henning Gruell ⁴, Florian Klein ^{2,4}, Christoph Wenisch ⁵, Michael Hallek ¹, Philipp Schommers ^{1,2,3,4*} and Clara Lehmann ^{1,2,3*}

*** Correspondence:** Clara Lehmann, clara.lehmann@uk-koeln.de

Supplementary Figures

Supplementary Figure 1




Figure S1. Stratified SARS-CoV-2 immunoglobulin G (IgG) titers (median (IQR) BAU/ml) based on **A** presence/absence of post-COVID syndrome (PCS), **B** sex and **C** age. PCS⁺, patients with PCS; PCS⁻, patients without PCS; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; IQR, interquartile range; BAU, binding antibody units; ml, milliliter; y, years.

Supplementary Tables

Supplementary Table 1

	female (n=52)	male (n=17)	total (N=69)
Age, years, median (IQR)	50 (34-57)	56 (47-63)	52 (38-60)
Pre-existing conditions, n (%)	19 (36.5)	4 (23.5)	23 (33.3)
Malignancies	5 (9.6)	0	5 (7.2)
Hypertension	5 (9.6)	2 (11.8)	7 (7.2)
Diabetes	2 (3.8)	2 (11.8)	4 (5.8)
Autoimmune disease	2 (3.8)	0	2 (2.9)
Chronic lung disease	1 (1.9)	2 (11.8)	3 (4.3)
WHO grade, n (%)			
I-III	52 (100.0)	17 (100.0)	69 (100.0)
Symptoms, n (%)			
Fatigue	35 (67.3)	10 (58.8)	45 (65.2)
Dyspnoea	23 (44.2)	3 (17.6)	26 (37.7)
Ageusia	16 (30.8)	8 (47.1)	24 (34.8)
Diarrhoea	11 (20.4)	5 (29.4)	16 (23.2)
Muscle and/or body aches	9 (18.5)	1 (5.9)	10 (14.5)
Anosmia	8 (16.7)	0 (0)	8 (11.6)
Fever	2 (3.8)	2 (11.8)	4 (5.8)
Headache	3 (5.6)	1 (5.9)	4 (5.8)
Sore throat	1 (1.9)	1 (5.9)	2 (2.9)
Cough	1 (1.9)	0 (0)	1 (1.4)
No symptoms	0 (0)	0 (0)	0 (0)
Distribution at month 15, n (%)			
SC1: Anosmia & Ageusia	1 (1.9)	0 (0)	1 (0.4)
SC2: Fatigue & Dyspnoea	16 (30.8)	1 (5.9)	17 (24.6)
SC3: Sore Throat & Cough	0 (0)	0 (0)	0 (0)
SC4: Headache	4 (7.7)	0 (0)	4 (5.8)
SC5: Diarrhoea	12 (8.7)	4 (23.5)	16 (23.2)
Vaccination status, n (%)			
Vaccinated at 15 months	42 (80.8)	10 (58.8)	52 (75.4)
Unvaccinated at 15 months	10 (19.2)	7 (41.2)	17 (24.6)
Working status at 15 months, n (%)			
Working again	40 (76.9)	11 (64.7)	51 (73.9)
Sick leave	7 (13.5)	4 (23.5)	11 (15.9)
Unknown	5 (9.6)	2 (11.8)	7 (10.1)

Table S1. Detailed patient characteristics of 69 PCS patients 15 months post-infection (T4).

PCS, post-COVID syndrome; WHO, world health organisation; T4, last study visit; N, population; n, sample size; IQR, interquartile range; y, years; n.a., not applicable.

Supplementary Table 2

	SARS-CoV-2 IgG titers [BAU/ml median (IQR)]				p-value vac ⁺ vs. vac ⁻
	T1	T2	T3	T4	
PCS					
PCS ⁺	107 (43-278)	34 (18-113)	38 (14-113)	2015 (234-4344)	<0.0001
PCS ⁻	113 (41-320)	59 (25-121)	41 (17-91)	2351 (327-4235)	
Age					
18-59 years	108 (43-260)	47 (20-110)	39 (14-90)	2308 (207-4432)	<0.0001
60-79 years	163 (44-588)	76 (30-181)	51 (22-152)	2797 (1521-4001)	
Sex					
female	163 (53-396)	57 (30-121)	40 (19-95)	2322 (197-4013)	<0.0001
male	94 (31-230)	42 (18-113)	40 (14-95)	2293 (349-4545)	
Symptom clusters (SC)					
SC1: Anosmia & Ageusia	145 (48-304)	50 (20-100)	55 (17-157)	479 (479-479)	>0.05
SC2: Fatigue & Dyspneae	33 (33-33)	20 (7-389)	71 (18-198)	3528 (1519-5056)	<0.0001
SC3: Sore Throat & Cough	107 (43-289)	57 (38-75)	1 (1-1)	n.a	n.a.
SC4: Headache	107 (32-278)	43 (21-113)	23 (9-43)	2618 (22-9814)	>0.05
SC5: Diarrhoea	152 (33-383)	21 (0-37)	14 (12-30)	1459 (374-3871)	<0.0001

Table S2. Distribution of SARS-CoV-2 IgG titers (BAU/ml) in stratified groups. Data information: For statistical analysis, non-parametric Kruskal-Wallis tests with Dunn's multiple comparisons were used. $p < 0.05$ shows statistical significance. PCS, post-COVID syndrome; SARS-CoV-2, severe acute respiratory syndrome coronavirus type 2; IgG, immunoglobulin G; BAU, binding antibody units; ml, milliliter; vac⁺, vaccinated; vs., versus; vac⁻, unvaccinated; N, population; n, sample size; IQR, interquartile range; n.a., not applicable

Supplementary Table 3

	female (n=136)	male (n=86)	total (N=222)	vaccinated (n=171)	unvaccinated (n=51)
Working status at 6 months, n (%)					
<i>Working again</i>	101 (74.3)	59 (68.6)	160 (72.0)	126 (73.7)	34 (66.7)
<i>Sick leave</i>	16 (11.8)	17 (19.8)	33 (14.9)	25 (14.6)	8 (15.7)
<i>Unknown</i>	19 (14.0)	10 (11.6)	29 (13.1)	20 (11.7)	9 (17.6)
Working status at 10 months, n (%)					
<i>Working again</i>	103 (75.7)	57 (66.3)	160 (72.1)	120 (70.2)	40 (78.4)
<i>Sick leave</i>	20 (14.7)	14 (16.3)	34 (15.3)	23 (13.5)	11 (21.6)
<i>Unknown</i>	13 (9.6)	15 (17.4)	28 (21.6)	28 (16.4)	0 (0)
Working status at 15 months, n (%)					
<i>Working again</i>	99 (69.9)	68 (79.1)	167 (75.2)	125 (73.1)	42 (82.4)
<i>Sick leave</i>	20 (14.7)	13 (15.1)	33 (14.9)	29 (17.0)	4 (7.8)
<i>Unknown</i>	17 (4.4)	5 (5.8)	22 (9.9)	17 (9.9)	5 (9.8)

Table S3. Working status of PCS patients at 6-, 10- and 15 months post-infection. PCS, post-COVID syndrome; n, sample size; %, percentage.